Get started

Earnings

Wix | WIX | Long at $124.35NASDAQ:WIX is a company with steady growth projections driven by AI adoption, market expansion, user acquisition, and a focus on profitability. For example, earnings are forecast to grow 28.24% per year. Analysts project NASDAQ:WIX to achieve approximately $1 billion in free cash flow by 2028. While the current P/E is around 47x, its Forward P/E ratio is approximately 18x (potentially undervalued). I truly believe the changing economy will shift individuals into more entrepreneurship (what else can they do?) and that will be the driving force behind user growth. From a technical analysis view, the price recently bounced off from my historical simple moving average band (often an area for share accumulation / consolidation). While it may trickle down to close the price gap on the daily chart near $110 in the near-term, I think the outlook needs to be long-term here given the projections. The only issue I see is the current high debt for NASDAQ:WIX , but interest rates are absolutely coming down soon which will help ease the strain. Thus, at $124.35, NASDAQ:WIX is in a personal buy zone. Targets into 2028: $175.00 (+40.7%) $250.00 (+101.1%)
NASDAQ:WIXLong
by WorthlessViews
JELD-WEN Holdings | JELD | Long at $4.02JELD-WEN Holdings NYSE:JELD designs, manufactures, and sells wood, metal, and composite materials doors, windows, and related building products in North America and Europe. The stock has taken quite a beating since the rise in interest rates, and I think a reversal *may* be in sight in the next year as rates are slowly lowered - even if the market is forward-thinking and purely anticipating a new housing boom (which I highly doubt given the current home prices). Regardless, there is risk with this stock since it has relatively high debt (debt-to-equity of 2.61x). A Quick Ratio of 1.1 and Altman's Z Score of 1.9 puts NYSE:JELD near a medium level of bankruptcy risk. The company has pretty good cash reserves and a forward P/E of 10x (current is negative), so growth is anticipated. Book value of $5.31. A bear case here is a terrible earnings call in August 2025 due to the housing market slowing (i.e. people pausing home purchases/builds/repairs expecting interest rates to drop soon). That may plummet the stock near $1.00 or below, which would be a tremendous deal, *unless* the company fundamentals change (like bankruptcy). Without a crystal ball, yet understanding the forward-thinking aspects of the market, NYSE:JELD is in a personal buy-zone at $4.02 with some risks. Targets into 2027: $5.40 (+34.3%) $8.50 (+111.4%)
NYSE:JELDLong
by WorthlessViews
KIMLUN - DMI and RSI shows BULLISH SIGNAL KIMLUN - CURRENT PRICE : RM1.31 KIMLUN is in an uptrend for medium term as the price is making higher high and higher low. Supported by positive readings in technical oscillators such as DMI (+DI is above -DI) and RSI (above 50), it increases the bullish scenario. At current price trading near SMA 20, there is possibility for price reach upper band in bollinger bands indicator. Nearest support will be RM1.24 (-5.34%) and 1st target will be RM1.41 (+7.63%). ENTRY PRICE : RM1.30 - RM1.31 TARGET : RM1.41 and RM1.47 SUPPORT : RM1.24 Notes : On the fundamental side, KIMLUN shows a strong recovery in earnings. For FY2022, company was loss RM7.2 million. Then the company rebounded with a profit of RM7.1 million in FY2023. For FY2024, company registered strong performance of profit RM50.3 million.
MYX:KIMLUNLong
by IMRAN_96
Novo Nordisk (Revised) | NVO | Long at $47.78**This is a revised analysis from February 5, 2025: I am still in that position, but added significantly more below $50** Novo Nordisk NYSE:NVO is now trading at valuations before its release of Wegovy and Ozempic... From a technical analysis perspective, it's within my "major crash" simple moving average zone (gray lines). When a company's stock price enters this region (especially large and healthy companies) I always grab shares - either for a temporary future bounce or a long-term hold. While currently trading near $47 a share, I think worst case scenario here in 2025 is near $38-$39. Tariffs may cause a recession in the second half of 2025, so no company would be immune. As mentioned above, I am still a holder at $86.74. However, I went in much heavier within my "major crash" simple moving average band and have a final entry planned near $38-$38 (if it drops there). My current cost average is near $55.00. Why do I still have faith in NYSE:NVO ? Because no one else does right now, yet it generated $42 billion in revenue, $14 billion in profits, and has significant cash flow YoY. The company has a massive pipeline, despite Wegovy and Ozempic competition, and I think the market is undervaluing its position in the pharmaceutical industry. Revised Targets in 2028: $60.00 (+25.6%) $70.00 (+46.5%) $80.00 (+67.4%)
NYSE:NVOLong
by WorthlessViews